Top 10 Companies in the Global Medical Grade Microcrystalline Cellulose Market (2026): Market Leaders Powering Pharmaceutical Innovation

MARKET INSIGHTS

The Global Medical Grade Microcrystalline Cellulose (MCC) market size was valued at USD 143.80 million in 2024. The market is projected to grow from USD 153.50 million in 2025 to USD 231.65 million by 2034, exhibiting a compound annual growth rate of 7.00% during the forecast period.

Medical Grade Microcrystalline Cellulose is a purified, partially depolymerized cellulose derived from wood pulp or refined cotton. It is widely used as a binder, disintegrant, and filler in pharmaceutical formulations, particularly in tablet and capsule production, due to its excellent compressibility, stability, and inert properties. The increasing demand for pharmaceutical excipients, coupled with the growth of the generics market, is a key driver for this sector.

The market is expanding due to rising pharmaceutical production, advancements in drug delivery systems, and stringent regulatory requirements for high-quality excipients. Additionally, the growing prevalence of chronic diseases necessitates increased drug formulations, further propelling demand. Leading manufacturers like DuPont, JRS Pharma, and Roquette are investing in capacity expansion and product innovation to meet industry needs. For instance, in 2023, DuPont announced an expansion of its MCC production capacity in the U.S. to cater to the rising pharmaceutical demand, strengthening its market position.

Global Medical Grade Microcrystalline Cellulose Market – View in Detailed Research Report

Top 10 Companies in the Global Medical Grade Microcrystalline Cellulose Market (2026)

1️⃣ DuPont

Headquarters: Wilmington, Delaware, USA
Key Offering: MCC grades for tablet and capsule formulations, advanced functionalized excipients

DuPont’s MCC portfolio is distinguished by a blend of high purity and tailored particle size distribution that supports direct compression processes across a broad spectrum of dosage forms. The company’s recent U.S. expansion reflects its commitment to meeting the growing demand for excipients in the generics sector.

Sustainability & Growth Initiatives: Investment in green manufacturing technologies to reduce energy consumption and carbon footprint.

• Enhanced direct compression grades with reduced moisture content.
• Partnerships with contract manufacturers to accelerate time‑to‑market.
• Launch of a new line of co‑processed MCC for controlled‑release applications.

2️⃣ JRS Pharma

Headquarters: Düsseldorf, Germany
Key Offering: High‑purity MCC for biopharmaceutical and specialty drug formulations

JRS Pharma focuses on delivering MCC that meets stringent USP and EP standards, enabling its use in parenteral and biologic drug products. The firm’s research division routinely collaborates with pharmaceutical developers to create excipients that support novel delivery platforms.

Sustainability & Growth Initiatives: Commitment to circular economy principles through waste‑to‑energy conversion of cellulose residues.

• Development of low‑microbial MCC for injectable applications.
• Strategic alliance with European generics manufacturers.
• Continuous improvement of particle engineering to enhance flowability.

3️⃣ Roquette

Headquarters: Courbevoie, France
Key Offering: Functionalized MCC for nutraceuticals and pharmaceuticals

Roquette’s MCC solutions are engineered to provide both binding and disintegration properties while maintaining a high level of inertness, making them suitable for both traditional tablets and emerging oral disintegrating formulations.

Sustainability & Growth Initiatives: Integration of renewable energy sources in production facilities.

• Launch of a new silicate‑co‑processed MCC line.
• Expansion of European manufacturing footprint.
• Partnerships with nutraceutical companies to support high‑volume production.

4️⃣ Asahi Kasei

Headquarters: Tokyo, Japan
Key Offering: MCC grades tailored for Asian market requirements and high‑volume generics

Asahi Kasei leverages its extensive R&D network in Asia to produce MCC that aligns with local regulatory standards and market preferences, ensuring seamless integration into regional pharmaceutical manufacturing pipelines.

Sustainability & Growth Initiatives: Adoption of water‑recycling systems in plant operations.

• Development of high‑purity MCC for pediatric formulations.
• Expansion of production capacity in China and India.
• Collaboration with local contract manufacturers to streamline supply chains.

5️⃣ Accent Microcell

Headquarters: Chennai, India
Key Offering: Cost‑effective MCC for the Indian generics market

Accent Microcell’s focus on delivering value‑oriented MCC solutions has positioned it as a preferred supplier for domestic manufacturers seeking to balance quality with price sensitivity.

Sustainability & Growth Initiatives: Implementation of waste‑water treatment and reuse protocols.

• Introduction of a new low‑cost MCC grade for tablet compression.
• Strategic partnership with local pharmaceutical companies.
• Investments in automation to improve production efficiency.

6️⃣ Sigachi

Headquarters: Bangalore, India
Key Offering: MCC with enhanced flow properties for high‑volume manufacturing

Sigachi’s MCC formulations are engineered to optimize flow and compressibility, supporting the rapid production of solid dosage forms in high‑throughput facilities.

Sustainability & Growth Initiatives: Deployment of renewable energy sources in manufacturing units.

• Launch of a new MCC grade with reduced moisture content.
• Expansion of domestic production capacity.
• Collaboration with contract manufacturers to reduce lead times.

7️⃣ Wei Ming Pharmaceutical

Headquarters: Taipei, Taiwan
Key Offering: MCC for both pharmaceutical and nutraceutical applications

Wei Ming Pharmaceutical supplies MCC that meets rigorous quality standards, enabling its use across a spectrum of dosage forms, from tablets to capsules.

Sustainability & Growth Initiatives: Integration of energy‑efficient production lines.

• Development of a new MCC grade with improved disintegration characteristics.
• Partnerships with regional pharmaceutical manufacturers.
• Investment in R&D to support emerging drug delivery technologies.

8️⃣ Mingtai

Headquarters: Shanghai, China
Key Offering: MCC for high‑volume generic drug manufacturing

Mingtai’s MCC solutions are tailored to meet the stringent demands of the Chinese pharmaceutical market, emphasizing consistency and scalability.

Sustainability & Growth Initiatives: Adoption of eco‑friendly processing techniques.

• Launch of a new high‑purity MCC line for advanced dosage forms.
• Expansion of production capacity in eastern China.
• Collaboration with local contract manufacturers to streamline supply chains.

9️⃣ Anhui Sunhere Pharmaceutical

Headquarters: Hefei, China
Key Offering: MCC grades for tablet and capsule manufacturing

Anhui Sunhere Pharmaceutical focuses on delivering MCC that aligns with both domestic and export regulatory requirements, supporting a wide array of dosage forms.

Sustainability & Growth Initiatives: Implementation of waste‑to‑energy conversion.

• Development of a new MCC grade with enhanced flowability.
• Expansion of production capacity in central China.
• Partnerships with regional manufacturers to support high‑volume production.

🔟 Shandong Guangda

Headquarters: Qingdao, China
Key Offering: MCC for tablet and capsule applications with a focus on cost efficiency

Shandong Guangda supplies MCC that balances high quality with competitive pricing, making it a popular choice among manufacturers seeking cost‑effective solutions.

Sustainability & Growth Initiatives: Use of renewable energy in plant operations.

• Introduction of a new low‑cost MCC grade for tablet compression.
• Expansion of domestic production capacity.
• Collaboration with contract manufacturers to enhance supply chain resilience.

Download FREE Sample Report

Get Full Report

Market Outlook

With the global pharmaceutical landscape shifting toward higher quality standards and patient‑centric formulations, the demand for medical grade MCC is set to intensify. The combination of rising generic drug production, the expansion of biologics, and the need for robust excipients in controlled‑release and orally disintegrating tablets will sustain the market’s growth trajectory through 2034.

Future Trends

• Digitalization of Supply Chains: Real‑time tracking and traceability of excipient sourcing will become essential for compliance and risk mitigation.
• Personalized Medicine: Customizable MCC grades tailored to individual patient needs will drive niche market development.
• Regulatory Alignment: Harmonization of global excipient standards will reduce barriers to international trade.
• Co‑Processing and Functionalization: Integration of MCC with other excipients to deliver multi‑functional properties will open premium segments.
• Green Manufacturing: Adoption of sustainable production practices will differentiate leaders in a market increasingly conscious of environmental impact.